| European Case Law Identifier: | ECLI:EP:BA:2004:T092600.20040226 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 26 February 2004 | ||||||||
| Case number: | T 0926/00 | ||||||||
| Application number: | 93923964.6 | ||||||||
| IPC class: | A61K 31/70 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Fludarabine-5' monophosphate for the treatment of autoimmune diseases | ||||||||
| Applicant name: | Schering Aktiengesellschaft | ||||||||
| Opponent name: | - | ||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request: novelty (yes) - use of fludarabine-5' monophosphate for the treatment of autoimmune diseases not directly and unambigously derivable from the cited state of the art; inventive step (no) - skilled person was provided with several hints and suggestions from the prior art pointing him in the direction of the claimed use: obvious to try Second, third and fourth auxiliary requests - idem First auxiliary request - contravention of Article 123(2) EPC |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t000926eu1.html
Date retrieved: 17 May 2021